CNS Helps to Bring Another Drug to Market - A New Antidepressant is now FDA Approved

ORLANDO, Fla. - Oct. 1, 2013 - PRLog -- CNS Healthcare is proud to announce that Brintellix™ (vortioxetine), an antidepressant assessed through our clinical trials, in partnership with Takeda Pharmaceuticals and Lundbeck, was approved by the US FDA on September 30, 2013 for the treatment of Major Depressive Disorder in adults.

Brintellix™ will be available in 5 mg, 10 mg, 15 mg and 20 mg tablets. It is an inhibitor of serotonin (5-HT) reuptake and that is thought to be a mechanism of its action. It is also an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3, 5-HT1D and 5-HT7 receptors. The contribution of each of these activities to Brintellix's antidepressant effect has not been established. It is considered to be the first and only compound with this combination of pharmacodynamic activity. The clinical relevance of this is unknown.

You can learn more by reading this article: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm

It is through clinical trials that potential new treatments, which can improve our patient's lives, can be identified. Persons who participate in our trials receive a comprehensive diagnostic evaluation.  Additionally, we monitor patient safety with routine physical exams, labs and ECGs at no cost. Average length of participation in these trials is approximately 3 months and some provide medication for up to a full year. There is no need for health insurance to participate and we provide a stipend to help cover the cost of time and travel.